A Study of SYH2082 Injection in Healthy Participants

Inclusion Criteria: * Fully understands the content, procedures, and possible adverse reactions of the study, and voluntarily signs the ICF before the study; * At screening, age 18-55 years (inclusive, at the time of signing the ICF), male or female; * At screening, body weight ≥50 kg for males and ≥45 kg for females; body mass index (BMI) between 19.0 and 35.0 kg/m2 (inclusive); * Body weight change ≤5% within 3 months prior to screening (including the screening period); * From the time of signing the ICF until 6 months after the last dose, the participant (including their partner) has no plans for childbirth and agrees to use highly effective contraceptive measures; Exclusion Criteria: * Known or suspected allergy to glucagon-like peptide-1 (GLP-1) or Glucose dependent insulinotropic polypeptide (GIP) receptor agonists or any component of the investigational product; or has an allergic constitution (allergic to multiple drugs and foods); * Abnormal results in vital signs, physical examination, laboratory tests, chest X-ray, ultrasound and ECG that are judged by the investigator to be clinically significant within the screening period. Specifically, the following conditions are not excluded: 1)Systolic blood pressure (SBP) \< 160 mmHg, diastolic blood pressure (DBP) \< 100 mmHg;2)Fasting TG ≤ 3.42 mmol/L, fasting TC ≤ 7.75 mmol/L(with abnormal HDL-C regardless of LDL-C status); 3)Alanine aminotransferase (ALT) \< 2 × ULN, aspartate aminotransferase (AST) \< 2 × ULN, gamma…